The V Foundation Adult Translational Cancer Grant 2027

The V Foundation Adult Translational Cancer Grant 2027

Due Date: 12/02/2026

The V Foundation Adult Translational Cancer Grant 2027 provides US$800,000 over four years for research that moves laboratory discoveries toward clinical use in adults with cancer. The call is open to projects across all adult cancer types.

Teams can propose moving a new strategy from the laboratory into a human clinical trial or using clinical trial specimens to test a hypothesis, develop biomarkers or investigate mechanisms. The project should lead to the planning or initiation of a new trial, or include an investigator-initiated trial with laboratory analyses that test the study hypothesis.

Eligibility Criteria

  • Each invited institution may nominate one candidate. Researchers should check with their grants office for its internal selection process and deadline.
  • The lead investigator at an invited U.S. institution must be a U.S. citizen or authorised to work in the United States. This requirement does not apply to nominees at invited Canadian institutions.
  • Proposals must focus on preclinical or translational research in adult cancer. Epidemiology, behavioural science and health services research are outside the scope.
  • The work must have a direct application to human health within three years after the grant ends.
  • Biomarker studies require a validation plan using a separate validation set or an independent clinical trial.
  • Full applications must include a detailed biostatistical or bioinformatics plan.

Funding Details

  • Total award: US$800,000 over four years, paid in annual instalments of US$200,000.
  • Indirect costs: Up to 10%, included in the total award.
  • Earliest award start: April 15, 2027.

Deadline

  • Institutional nomination: December 2, 2026, at 5:00 p.m. U.S. Eastern Time.
  • Full application: January 6, 2027, at 4:00 p.m. U.S. Eastern Time.
  • Internal deadlines: Vary by institution and may precede the sponsor’s nomination deadline.

Further Information